benzimidazole and Infections, Respiratory

benzimidazole has been researched along with Infections, Respiratory in 1 studies

1H-benzimidazole : The 1H-tautomer of benzimidazole.

Research

Studies (1)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Percentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12)

Sustained virologic response 12 weeks post-treatment (SVR12) was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (LLOQ; less than 15 IU/mL) 12 weeks after the last dose of study drug. (NCT03222583)
Timeframe: 12 weeks after the last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen.

Percentage of HCV GT1-Infected Participants in Arm A Who Achieved SVR12

SVR12 was defined as plasma HCV RNA level less than 15 IU/mL 12 weeks after the last dose of study drug. (NCT03222583)
Timeframe: 12 weeks after last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen

Percentage of HCV GT2-Infected Participants in Arm A Who Achieved SVR12

SVR12 was defined as plasma HCV RNA level less than 15 IU/mL 12 weeks after the last actual dose of study drug. (NCT03222583)
Timeframe: 12 weeks after the last dose of study drug, Week 20 or Week 28 depending on the treatment regimen.

Percentage of Participants in Arm A With On-treatment Virologic Failure

"On-treatment virologic failure was defined as meeting one of the following:~confirmed increase from nadir in HCV RNA (two consecutive HCV RNA measurements > 1 log₁₀ IU/mL above nadir) at any time point during the treatment period; or~confirmed HCV RNA greater than or equal to 100 IU/mL after HCV RNA < 15 IU/mL during the treatment period, or~HCV RNA ≥ 15 IU/mL at end of treatment with at least 6 weeks of treatment." (NCT03222583)
Timeframe: 8 or 16 weeks depending on the treatment regimen

Percentage of Participants in Arm A With Post-treatment Relapse

Post-treatment relapse was defined as confirmed HCV RNA greater than or equal to 15 IU/mL between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels < 15 IU/mL at the end of treatment, excluding re-infection. (NCT03222583)
Timeframe: From the end of treatment (Weeks 8 or 16) through 12 weeks after the last dose of study drug (Weeks 20 or 28 depending on the treatment regimen).

Percentage of Participants With On-treatment Virologic Failure

"On-treatment virologic failure was defined as meeting one of the following:~confirmed increase from nadir in HCV RNA (two consecutive HCV RNA measurements > 1 log₁₀ IU/mL above nadir) at any time point during the treatment period; or~confirmed HCV RNA greater than or equal to 100 IU/mL after HCV RNA < 15 IU/mL during the treatment period, or~HCV RNA ≥ 15 IU/mL at end of treatment with at least 6 weeks of treatment." (NCT03235349)
Timeframe: 12 or 16 weeks depending on the treatment regimen

Percentage of Participants With Post-treatment Relapse

Post-treatment relapse was defined as confirmed HCV RNA greater than or equal to 15 IU/mL between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels < 15 IU/mL at the end of treatment, excluding re-infection. (NCT03235349)
Timeframe: From the end of treatment (Week 12 or 16) through 12 weeks after the last dose of study drug (Weeks 24 or 28 depending on the treatment regimen).

Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (LLOQ; 15 IU/mL) 12 weeks after the last dose of study drug. (NCT03235349)
Timeframe: 12 weeks after the last actual dose of study drug, Week 24 or Week 28 depending on the treatment regimen.

Trials

1 trial available for benzimidazole and Infections, Respiratory